Exportar registro bibliográfico


Metrics:

Kynurenine is correlated with IL-1 beta in plasma of schizophrenia patients (2018)

  • Authors:
  • Autor USP: GATTAZ, WAGNER FARID - FM
  • Unidade: FM
  • DOI: 10.1007/s00702-018-1838-8
  • Subjects: ESCALAS DE GRADUAÇÃO PSIQUIÁTRICA; PSICODIAGNÓSTICO; ESQUIZOFRENIA; INFLAMAÇÃO; CITOCINAS
  • Agências de fomento:
  • Language: Inglês
  • Imprenta:
    • Publisher place: Wien
    • Date published: 2018
  • Source:
  • Acesso à fonteDOI
    Informações sobre o DOI: 10.1007/s00702-018-1838-8 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      JOAQUIM, Helena P. G.; COSTA, Alana C.; GATTAZ, Wagner F.; TALIB, Leda Leme. Kynurenine is correlated with IL-1 beta in plasma of schizophrenia patients. Journal of neural transmission, Wien, v. 125, n. 5, p. 869-873, 2018. Disponível em: < http://dx.doi.org/10.1007/s00702-018-1838-8 > DOI: 10.1007/s00702-018-1838-8.
    • APA

      Joaquim, H. P. G., Costa, A. C., Gattaz, W. F., & Talib, L. L. (2018). Kynurenine is correlated with IL-1 beta in plasma of schizophrenia patients. Journal of neural transmission, 125( 5), 869-873. doi:10.1007/s00702-018-1838-8
    • NLM

      Joaquim HPG, Costa AC, Gattaz WF, Talib LL. Kynurenine is correlated with IL-1 beta in plasma of schizophrenia patients [Internet]. Journal of neural transmission. 2018 ; 125( 5): 869-873.Available from: http://dx.doi.org/10.1007/s00702-018-1838-8
    • Vancouver

      Joaquim HPG, Costa AC, Gattaz WF, Talib LL. Kynurenine is correlated with IL-1 beta in plasma of schizophrenia patients [Internet]. Journal of neural transmission. 2018 ; 125( 5): 869-873.Available from: http://dx.doi.org/10.1007/s00702-018-1838-8

    Referências citadas na obra
    Barry S, Clarke G, Scully P, Dinan TG (2009) Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol 23:287–294
    Bramon E, Sham PC (2001) The common genetic liability between schizophrenia and bipolar disorder: a review. Curr Psychiatry Rep 3:332–337
    Brown AS, Susser ES (2002) In utero infection and adult schizophrenia. Ment Retard Dev Disabil Res Rev 8:51–57
    Campbell BM, Charych E, Lee AW, Möller T (2014) Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci 8:12
    Dounay AB, Tuttle JB, Verhoest PR (2015) Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway. J Med Chem 58:8762–8782
    Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E et al (2006) Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 163:521–528
    Erhardt S, Oberg H, Mathé JM, Engberg G (2001) Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 20:353–362
    Erhardt S, Schwieler L, Imbeault S, Engberg G (2017) The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology 112:297–306
    Fazio F, Lionetto L, Curto M, Iacovelli L, Cavallari M, Zappulla C, Ulivieri M, Napoletano F, Capo M, Corigliano V, Scaccionoce S, Caruso A, Miele J, De Fusco A, Di Menna L, Comparelli A, De Carolis A, Grandini R, Nistico R, De Blasi A, Girardi P, Bruno V, Battaglia G, Nicoletti F, Simmaco M (2015) Xanthurenic acid activates mGlu2/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia. Sci Rep 5:17799
    Fillman SG, Cloonan N, Miller LC, Weickert CS (2013) Markers of inflammation in the prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 18:133
    First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured clinical interview for DSM-IV-TR axis I disorders. Research version. Non-patient edition (SCID-I/NP). Biometrics Research, New York State Psychiatric Institute, New York
    Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, Ishiguro H, Seishima M (2006) The signal transducer and activator of transcription 1 alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J Biochem 139:655–662
    Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56:2007–2017
    Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Ursonomiya M, Nakatani M, Sadamoto K, Yoshio T (2014) Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One 9:101652
    Gal EM, Sherman AD (1980) l-Kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res 5:223–239
    Garver DL, Tamas RL, Holcomb JÁ (2003) Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology 28:1515–1520
    Haber R, Bessette D, Hulihan-Giblin B, Durcan MJ, Goldman D (1993) Identification of tryptophan 2,3-dioxygenase RNA in rodent brain. J Neurochem 60:1159–1162
    Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463–7473
    Jospeh MH, Baker HF, Crow TJ, Riley GJ, Risby D (1979) Brain tryptophan metabolism in schizophrenia: a post mortem study of metabolites of the serotonin and kynurenine pathways in schizophrenic and control subjects. Psychopharmacology 62:279–285
    Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale for schizophrenia. Schizophr Bull 13:261–276
    Kegel ME, Svensson CI, Erhardt S (2011) IL-1 induces IDO and TDO transcription and provokes the release of kynurenic acid from human astrocytes in vitro. Progr No 24019/E7 Neurosci Meet Planner Washington, DC. Soc Neurosci Online
    Lake CR, Hurwitz N (2007) Schizoaffective disorder merges schizophrenia and bipolar disorders as one disease—there is no schizoaffective disorder. Curr Opin Psychiatry 20:365–379
    Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM (2009) Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373:234–239
    Linderholm KR, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G, Samuelsson M, Erhardt S (2012) Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 38:426–432
    Mándi Y, Vécsei L (2012) The kynurenine system and immunoregulation. J Neural Transm 119:197–209
    Miller CL, Llenos IC, Dulay JR, Weis S (2006) Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 1074:25–37
    Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpe S, Steinbusch HW, Leonard BE, Kim YK (2011) Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav Immun 25:1576–1581
    Okusaga O, Fuchs D, Reeves G, Giegling I, Hartmann AM, Konte B, Friedl M, Groer M, Cook TB, Stearns-Yoder KA, Pandey JP, Kelly DL, Hoisington AJ, Lowry CA, Eaton WW, Brenner LA, Rujescu D, Postolache TT (2016) Kynurenine and tryptophan levels in patients with schizophrenia and elevated antigliadin immunoglobulin G antibodies. Psychosom Med 78:931–939
    Owen MJ, Craddock N (2009) Diagnosis of functional psychoses: time to face the future. Lancet 373:190–191
    Plitman E, Iwata Y, Caravaggio F, Nakajima S, Chung JK, Gerretsen P, Kim J, Takeuchi H, Chakravarty MM, Remington G, Graff-Guerrero A (2017) Kynurenic acid in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 43:764–777
    Raison CL, Miller AH (2004) Brain–immune system interaction: relevance to the pathophysiology and treatment of neuropsychiatric disorders. In: Schatzberg AF, Nemeroff CB (eds) The American psychiatric publishing textbook of psychopharmacology, 3rd edn. American Psychiatric Press, Washington, pp 147–162
    Rao JS, Kim HW, Harry GJ, Rapoport SI, Reese EA (2013) Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophr Res 147:24–31
    Ravikumar A, Deepadevi KV, Arun P, Manojkumar V, Kurup PA (2000) Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders. Neurol India 48:231–238
    Saito K, Crowley JS, Markey SP, Heyes MP (1993) A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. J Biol Chem 268:15496–15503
    Sasayama D, Hattori K, Wakabayashi C, Teraishi T, Hori H, Ota M, Yoshida S, Arima K, Higuchi T, Amano N, Kunugi H (2013) Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res 47:401–406
    Sathyasaikumar KV, Stachowski EK, Wonodi I, Roberts RC, Rassoulpour A, McMahon RP, Schwarcz R (2011) Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull 37:1147–1156
    Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521–530
    Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (2012) Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 13:465–477
    Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, Finn A, Bhat M, Samuelsson M, Lundberg K, Dahl ML, Sellgren C, Schuppe-Koistinen I, Svensson C, Erhardt S, Engberg G (2015) Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia-significance for activation of the kynurenine pathway. J Psychiatry Neurosci 40:126–133
    Sellgren CM, Kegel ME, Bergen SE, Ekman CJ, Olsson S, Larsson M, Vawter MP, Backlund L, Sullivan PF, Sklar P, Smoller JW, Magnusson PK, Hultman CM, Walther-Jallow L, Svensson CI, Lichtenstein P, Schalling M, Engberg G, Erhardt S, Landén M (2016) A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. Mol Psychiatry 21:1342–1350
    Söderlund J, Schröder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H, Erhardt S, Engberg G (2009) Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry 14:1069–1107
    Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309–379
    Stone TW, Forrest CM, Mackay GM, Stoy N, Darlington LG (2007) Tryptophan, adenosine, neurodegeneration and neuroprotection. Metab Brain Dis 22:337–352
    Upthegrove R, Manzanares-Teson N, Barnes NM (2014) Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res 155:101–108
    Vécsei L, Szalárdy L, Fülöp F, Toldi J (2013) Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 12:64–82
    Wonodi I, Schwarcz R (2010) Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull 36(2):211–218

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2021